PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision repair, may correlate with clinical response to platinum agents. We found that most primary lung tumor specimens demonstrated a stronger protein expression of poly (adenosine diphosphate ribose) polymerases 1 (PARP1) than their normal counterparts. Therefore, we hypothesized that combining PARP inhibition with platinum compounds may be an approach to improve platinum-based therapy for NSCLC. Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model. Furthermore, mechanistic studies indicated that combined PARP inhibitor and cisplatin could lead to sustained DNA double-strand breaks, prolonged G2/M cell cycle arrest with distinct activation of checkpoint kinase 1 signaling and more pronounced apoptosis preferentially in lung cancer cells with low ERCC1 expression. Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188 · cited 1×
“Clonogenic survival was assayed as described previously (24).”
MethodCellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801 · cited 1×
“Platinum–DNA adducts are removed mainly by the nucleotide excision repair (NER) pathway (3).”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“Phase II clinical trials further demonstrated the efficacy and safety of olaparib in BRCA-associated breast and ovarian cancers (17,18).”
BackgroundOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“Moreover, a recent randomized phase II study demonstrated that maintenance therapy with olaparib could provide a significant improvement in progression-free survival in patients with platinumsensitive relapsed serous ovarian cancer (19).”
BackgroundDNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727 · cited 1×
“When evaluated in clinical trials, the International Adjuvant Lung Cancer Trial demonstrated that only ERCC1 low/negative but not ERCC1 high/positive tumors had a survival benefit from cisplatin-based adjuvant chemotherapy (7).”
MethodTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · cited 1×
“Inhibition of poly (adenosine diphosphate ribose) polymerases (PARPs), key components of base excision repair, have been shown to enhance platinum sensitivity in BRCA-associated breast and ovarian cancers (11,12).”
BackgroundThe ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276 · cited 2×
“We then examined the ATR-CHK1 and ATM-CHK2 pathways, which are two principal mechanisms activated by DNA damage and their activation is involved in regulating cell cycle arrest in late G1, intra-S and G2 phases (32).”
BackgroundMethod(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773 · cited 3×
“In addition to olaparib, an alternative PARP1/2 inhibitor, veliparib (ABT-888) (16) was also examined.”
BackgroundInfluentialPlatinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751 · cited 1×
“Enhanced DNA repair can lead to increased cell viability in the face of DNA damage and has been proposed to be important in mediating platinum resistance (2).”
BackgroundArdizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602 · cited 1×
“On the other hand, in addition to its role in DNA single-strand break repair, PARP1 is also activated at stalled replication forks and plays an important role in restarting stalled replication forks (42,43).”
BackgroundCobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 335 · cited 1×
“Increasing concentrations of cisplatin (1, 3 and 10 μM) with or without the PARP inhibitors, olaparib were added on day 1 (14).”
BackgroundSelvakumaran, M., Pisarcik, D., Bao, R., Yeung, A. T., & Hamilton, T. C. (2003) · PubMed · Cited by 317
Preclinical versus clinical drug combination studies
Chou, T.-C. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190802353591 · Cited by 302
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Yang, Y.-G., Cortes, U., Patnaik, S., Jasin, M., & Wang, Z.-Q. (2004) · Oncogene · doi:10.1038/sj.onc.1207491 · Cited by 242
Sorenson, C. M., & Eastman, A. R. (1988) · PubMed · Cited by 224
Zhang, Z., Kobayashi, S., Borczuk, A. C., Leidner, R. S., LaFramboise, T., Levine, A. D., & Halmos, B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq020 · Cited by 186
Self-citationA high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Lord, C. J., McDonald, S., Swift, S., Turner, N. C., & Ashworth, A. (2008) · DNA Repair · doi:10.1016/j.dnarep.2008.08.014 · Cited by 178
PARP Inhibitor Treatment in Ovarian and Breast Cancer
Weil, M. K., & Chen, A. P. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2010.12.002 · Cited by 162
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
Rosell, R., Perez-Roca, L., Sanchez, J. J., Cobo, M., Moran, T., Chaib, I., Provencio, M., Domine, M., Sala, M. A., Jimenez, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005133 · Cited by 161
Vilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 150 · cited 1×
“Cisplatin and olaparib were added for 3 days, whereas veliparib was present for the entire duration of the experiment as described previously (25).”
Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner, K., & Melton, D. W. (2010) · PubMed · Cited by 128
Orelli, B., McClendon, T. B., Tsodikov, O. V., Ellenberger, T., Niedernhofer, L. J., & Schärer, O. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067538 · Cited by 116 · cited 1×
“Besides its well-described role in NER, it also has been reported to function in ICL repair, DSB repair and homologous recombination (4,40).”
BackgroundAnderson, V. E., Walton, M. I., Eve, P. D., Boxall, K. J., Antoni, L., Caldwell, J. J., Aherne, W., Pearl, L. H., Oliver, A. W., Collins, I., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1252 · Cited by 109
Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T., & Reed, E. (1993) · Carcinogenesis · doi:10.1093/carcin/14.10.2177 · Cited by 101
Al-Minawi, A. Z., Lee, Y.-F., Hakansson, D., Johansson, F., Lundin, C., Saleh-Gohari, N., Schultz, N. D., Jenssen, D., Bryant, H. E., Meuth, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp705 · Cited by 97 · cited 1×
“For instance, ERCC1 was found to be essential for the completion of homologous recombination involved in repairing DNA DSBs caused by ICLs at a step downstream of RAD51 foci formation (41).”
BackgroundChang, I. Y., Kim, M.-H., Kim, H.-B., Lee, D. Y., Kim, S., Kim, H.-Y., & You, H. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.008 · Cited by 91 · cited 1×
“Additionally, in agreement with previous reports (35), ERCC1 depletion led to increased sensitivity to cisplatin.”
ResultChen, S., Zhang, J., Wang, R., Luo, X., & Chen, H. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.05.010 · Cited by 84 · cited 1×
“In addition, a meta-analysis of 12 studies (836 patients) in advanced lung cancer showed a higher response rate to platinum regimens in patients with low ERCC1 expression as compared with patients with high ERCC1 expression (47% versus 28%) (9).”
BackgroundZhu, G., & Lippard, S. J. (2009) · Biochemistry · doi:10.1021/bi900389b · Cited by 80 · cited 1×
“PARP1 constitutes >80% of overall PARP activity and has been identified as a platinum–DNA damage response protein (13).”
BackgroundPierceall, W. E., Olaussen, K. A., Rousseau, V., Brambilla, E. M., Sprott, K. M., André, F., Pignon, J., Chevalier, T. L., Pirker, R., Jiang, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr624 · Cited by 69 · cited 1×
“Interestingly, a recent report using specimens from the International Adjuvant Lung Cancer Trial-Bio study further indicated that the predictive role of ERCC1 on cisplatin benefits may correlate with the histological subtype of lung cancers such as that ERCC1 displayed significant predictive power in squamous cell car…”
ResultArdizzoni, A., Tiseo, M., Boni, L., Rosell, R., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D. Z., Paccagnella, A., Mazzanti, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7011 · Cited by 62
BRCA1: A New Genomic Marker for Non–Small-Cell Lung Cancer
Reguart, N., Cardona, A. F., Carrasco, E., Gómez, P. M. D., Tarón, M., & Rosell, R. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.048 · Cited by 55
Gandara, D. R., Grimminger, P., Mack, P. C., Lara, P. N., Li, T., Danenberg, P. V., & Danenberg, K. D. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd418d · Cited by 52 · cited 1×
“The ERCC1-low HCC827 and PC9 cells both harbor activating epidermal growth factor receptor mutations, and in concert with our findings, it has been reported that lung cancers with epidermal growth factor receptor activating mutations are more probably to be associated with low ERCC1 levels (34).”
Paul, I., Savage, K. I., Blayney, J. K., Lamers, E., Gately, K. A., Kerr, K. M., Sheaff, M. T., Arthur, K., Richard, D. J., Hamilton, P. W., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2925 · Cited by 38
Pétersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., & Bohr, V. A. (1996) · Carcinogenesis · doi:10.1093/carcin/17.12.2597 · Cited by 37
Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma
Peng, H., Wen, J., Li, H., Chang, J., & Zhou, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014750 · Cited by 33 · cited 1×
“The Bliss model was used to calculate the combination index (CI) and to evaluate the effects of drug combinations (26).”
MethodBrozović, A., Damrot, J., Tsaryk, R., Helbig, L., Nikolova, T., Hartig, C., Osmak, M., Roos, W. P., Kaina, B., & Fritz, G. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.07.002 · Cited by 32 · cited 1×
“Consistent with our cell cycle data, a recent study has demonstrated that the cellular sensitivity to cisplatin was due to delayed DNA damage processing and cell cycle control rather than damage response during the early times (45).”
BackgroundThe knock-down of ERCC1 but not of XPF causes multinucleation.
Rageul, J., Frémin, C., Ezan, F., Baffet, G., & Langouët, S. (2011) · DNA Repair · doi:10.1016/j.dnarep.2011.07.005 · Cited by 29 · cited 1×
“In line with our observations, a recent report suggested an essential role for ERCC1 in mitotic progression (44).”
Iniparib in Metastatic Triple-Negative Breast Cancer
Domagała, P., Lubiński, J., & Domagała, W. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101855 · Cited by 20
Wang, X., Li, G., Wang, A., Zhang, Z., Merchan, J. R., & Halmos, B. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21846 · Cited by 19 · cited 1×
“As described previously (28), total RNAs were collected using RNeasy Mini Kit (Qiagen, Germantown, MD) from cells.”
MethodSelf-citation
Research works printed but not linked: 3
- KIRSCHNER, 2010, Anticancer Research, 30, 3223
- Selvakumaran, 2003, Cancer Research, 63, 1311
- Sorenson, 1988, Cancer Research, 48, 6703
Cited by
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
“Combination strategies with olaparib and chemotherapeutic agents have shown to be effective in ERCC1 or PTEN-deficient lung cancer cells, showing that other deficiencies in DNA-repair pathways frequently occurring in NSCLC might have an impact on the response to olaparib treatment, and consequently also on this combin…”
BackgroundTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
“Early preclinical data has found PARP inhibition sensitized SCLC to cisplatin therapy (67).”
BackgroundDrugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D., Lee, S.-H., Williamson, E. A., & Hromas, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 159
Metadata
- Authors
- Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Mount Sinai Hospital (US)
- Columbia University Irving Medical Center (US)
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-28
- Volume
- 34
- Issue
- 4
- Pages
- 739-749
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- PMC
- PMC3616665
- OpenAlex
- W2135915034
- Cited by
- 99
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 18 · 2020: 4 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 3
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Carcinogenesis (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health (5k12ca132783-12)
- National Cancer Institute (CA 130536, 5K12CA132783-04, R01CA130536)
- National Institute of General Medical Sciences (R01GM079107, GM079107)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibition, cisplatin, ERCC1, non-small cell lung cancer, olaparib, veliparib, nucleotide excision repair, drug synergy, DNA double-strand breaks, G2/M cell cycle arrest, apoptosis, tumor markers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Checkpoint Kinase 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Cisplatin, DNA-Binding Proteins, Drug Synergism, Endonucleases, Humans, Lung Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Kinases, Apoptosis, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, DNA Breaks, Double-Stranded, G2 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.